By Ethan Covey
The variant-adapted bivalent BNT162b2 vaccine (bivalent BNT162b2, Pfizer-BioNTech) has a similar safety profile as the original BNT162b2 vaccine, and induced robust omicron BA.4/BA.5 and ancestral strain neutralizing titers when used as a booster dose in toddlers and children ages 6 through 59 months, according to data presented at IDWeek 2023, held in Boston (poster 362).
The substudy focused on data from a larger phase 1 to 3 master study that is looking into the safety and